【正文】 6(2): 9199.[33] Varghese ., Laver . and Colman . Structure of the influenza virus glycoprotein antigen neuraminidase at A resolution [J]. Nature, 1983, 303(5912): 3540.[34] von Itzstein M., Wu ., Kok ., et al. Rational design of potent sialidasebased inhibitors of influenza virus replication [J]. Nature, 1993, 363(6428): 418423.[35] Kim ., Lew W., Williams ., et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent antiinfluenza activity [J]. J Am Chem Soc, 1997, 119(4): 681690.[36] Ikematsu H. and Kawai N. Laninamivir octanoate: a new longacting neuraminidase inhibitor for the treatment of influenza [J]. Expert Rev Anti Infect Ther, 2011, 9(10): 851857.[37] Nguyen ., Fry . and Gubareva . Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods [J]. Antivir Ther, 2012, 17(1 Pt B): 159173.[38] Abed Y., Baz M. and Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds [J]. Antivir Ther, 2006, 11(8): 971976.[39] Gubareva ., Matrosovich ., Brenner ., et al. Evidence for zanamivir resistance in an immunopromised child infected with influenza B virus [J]. J Infect Dis, 1998, 178(5): 12571262.[40] Sheu ., Deyde ., OkomoAdhiambo M., et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008 [J]. Antimicrob Agents Chemother, 2008, 52(9): 32843292.[41] Hanessian S., Wang J., Montgomery D., et al. Design, synthesis, and neuraminidase inhibitory activity of GS4071 analogues that utilize a novel hydrophobic paradigm [J]. Bioorg Med Chem Lett, 2002, 12(23): 34253429.[42] Bhatt B., B246。hm R., Kerry ., et al. Exploring the Interactions of Unsaturated Glucuronides with Influenza Virus Sialidase [J]. Journal of Medicinal Chemistry, 2012, 55(20): 89638968.[43] Russell ., Haire ., Stevens ., et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design [J]. Nature, 2006, 443(7107): 4549.[44] Mohan S., McAtamney S., Haselhorst T., et al. Carbocycles Related to Oseltamivir as Influenza Virus Group1Specific Neuraminidase Inhibitors. Binding to N1 Enzymes in the Context of Viruslike Particles [J]. Journal of Medicinal Chemistry, 2010, 53(20): 73777391.[45] Kerry ., Mohan S., Russell ., et al. Structural basis for a class of nanomolar influenza A neuraminidase inhibitors [J]. Sci Rep, 2013, 3: 2871.[46] Mohan S., Kerry ., Bance N., et al. Serendipitous discovery of a potent influenza virus a neuraminidase inhibitor [J]. Angew Chem Int Ed Engl, 2014, 53(4): 10761080.[47] Schade D., Kotthaus J., Riebling L., et al. Development of Novel Potent Orally Bioavailable Oseltamivir Derivatives Active against Resistant Influenza A [J]. J Med Chem, 2014, 57(3): 759769.[48] Cheng ., Weinheimer S., Tarbet ., et al. Development of Oseltamivir Phosphonate Congeners as Antiinfluenza Agents [J]. Journal of Medicinal Chemistry, 2012, 55(20): 86578670.[49] Kim ., Resende R., Wennekes T., et al. Mechanismbased covalent neuraminidase inhibitors with broadspectrum influenza antiviral activity [J]. Science, 2013, 340(6128): 7175.